Taking Wegovy with Hypothyroidism: What You Need to Consider

What the evidence actually says about Wegovy and thyroid conditions

The NHS patient information for semaglutide lists the people who should not use it: those with a personal or family history of medullary thyroid carcinoma, and those with MEN2. Common hypothyroidism (whether Hashimoto's thyroiditis, post-surgical, or idiopathic) is a different matter entirely and does not appear on that list. The concern about thyroid tumours in GLP-1 medicines originated from rodent studies; current evidence in humans has not established the same risk, but the precautionary stance for MTC/MEN2 remains firm.

For people with autoimmune or primary hypothyroidism who are stable on levothyroxine, the practical consideration shifts to absorption. Semaglutide slows gastric emptying, which could theoretically alter how consistently levothyroxine is absorbed, particularly if the tablet is taken close to food or other medicines. Your endocrinologist or GP may want to check thyroid function a few months after starting Wegovy, and it is worth flagging this directly at your consultation. Transparency about your thyroid medication and recent TSH results helps the prescriber make the right call.

For a related thyroid picture, our page on how the considerations change when the thyroid is overactive rather than underactive covers the distinct clinical picture that comes with hyperthyroidism.

The decision your prescriber is making, and what tips it either way

Think of this as a structured clinical weighing of factors rather than a yes/no gate. A prescriber reviewing your consultation will typically consider: is your hypothyroidism treated and stable, with TSH in an acceptable range? Do you have a history of MTC or MEN2 in yourself or close relatives? Are there any other conditions alongside the thyroid issue (cardiovascular disease, type 2 diabetes) that change the benefit/risk calculation? Our detailed guide to Wegovy and hypothyroidism covers the clinical pathway in greater depth.

Stable, well-managed hypothyroidism on its own rarely rules someone out. What tends to matter more is the broader picture: BMI, comorbidities, medication list and the MTC/MEN2 family history check. If your thyroid function has been erratic recently, or if you have recently changed your levothyroxine dose, a prescriber may want more information before proceeding. That is good clinical practice, not a barrier. You can read more about how different health conditions interact with eligibility on our Wegovy and heart failure page, which shows the same structured approach applied to a different comorbidity.

The NICE technology appraisal for semaglutide (TA875) sets the eligibility framework for NHS access and gives prescribers the evidence base they are working from. Private prescribers follow the same licensed criteria.

How to approach a consultation when you have hypothyroidism

Come prepared with a few specifics: your current levothyroxine dose, your most recent TSH result if you have it, and any other thyroid-related history (surgery, radioiodine, family members with thyroid cancer). If you have an overactive rather than underactive thyroid, our page on whether Wegovy is suitable when hyperthyroidism is part of your history addresses the different considerations that apply. The consultation at nume is reviewed by a GPhC-registered prescriber (a real clinician reads your answers, not an automated system) and they will ask follow-up questions if anything needs clarifying before a decision is made.

Once approved as clinically suitable, your treatment is dispatched the same day for free next-working-day tracked delivery via DPD, arriving in plain, unbranded packaging. There is nothing on the outside of the box to indicate what is inside. Thyroid monitoring does not stop after you start: your GP should continue reviewing your thyroid function at their usual intervals, and worth mentioning to them that you have started Wegovy so they can schedule a TSH check accordingly. Our FAQs page covers general questions about the consultation process if you want to know what to expect before you begin.

People with hypothyroidism who are also managing type 2 diabetes may find the Wegovy and type 2 diabetes page useful alongside this one, since the two conditions frequently overlap and the prescriber will consider both when reviewing your suitability.

What we don't yet know, and who to talk to

Long-term data specifically examining semaglutide outcomes in people with hypothyroidism are limited. The major trials (including STEP 1, published in the New England Journal of Medicine) enrolled adults with obesity or overweight, and participants with thyroid disease were not uniformly excluded, but the trials were not designed to isolate thyroid-condition subgroups. So the honest answer is: we know enough to make an informed clinical decision for most people with stable hypothyroidism, but we do not have the same granular subgroup data that a specialist would have for, say, cardiovascular disease.

If your hypothyroidism is complex (managed by an endocrinologist, associated with other autoimmune conditions, or only recently diagnosed) it is worth involving that specialist in the conversation before starting any weight-management medicine. Your GP is the right first port of call for that liaison. For more on how the service works and the clinical team behind it, visit our about us page. If you are ready to discuss your situation directly with a prescriber, start your free consultation and share your thyroid history in full, it is the safest and most straightforward route to an answer that is specific to you.